Callahan Advisors LLC Decreases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Callahan Advisors LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,334 shares of the company's stock after selling 547 shares during the period. Callahan Advisors LLC's holdings in Eli Lilly and Company were worth $11,066,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. AMF Tjanstepension AB increased its position in shares of Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company's stock worth $293,964,000 after purchasing an additional 176,552 shares in the last quarter. Values Added Financial LLC increased its position in shares of Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company's stock worth $324,000 after purchasing an additional 17 shares in the last quarter. Trilogy Capital Inc. increased its position in shares of Eli Lilly and Company by 3.9% during the third quarter. Trilogy Capital Inc. now owns 1,347 shares of the company's stock worth $1,193,000 after purchasing an additional 51 shares in the last quarter. James Hambro & Partners LLP increased its position in shares of Eli Lilly and Company by 3.7% during the third quarter. James Hambro & Partners LLP now owns 340 shares of the company's stock worth $301,000 after purchasing an additional 12 shares in the last quarter. Finally, Bluesphere Advisors LLC increased its position in shares of Eli Lilly and Company by 1.7% during the third quarter. Bluesphere Advisors LLC now owns 966 shares of the company's stock worth $856,000 after purchasing an additional 16 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on LLY. Redburn Atlantic raised Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Wolfe Research initiated coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,000.00 target price on the stock. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $997.50.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $1.00 during mid-day trading on Friday, hitting $874.12. 3,937,537 shares of the stock were exchanged, compared to its average volume of 3,765,032. The firm has a fifty day moving average of $799.63 and a 200 day moving average of $846.07. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a market cap of $829.82 billion, a PE ratio of 74.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company's dividend payout ratio is presently 51.24%.

Eli Lilly and Company declared that its Board of Directors has authorized a share buyback plan on Monday, December 9th that authorizes the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.